4.7 Article

Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease

Journal

Publisher

AMER THORACIC SOC
DOI: 10.1164/rccm.202106-1404OC

Keywords

chronic obstructive pulmonary disease; alpha-1 antitrypsin; meta-analysis; RNA sequencing

Funding

  1. NIH [R01HL130512, R01HL125583, U01HL089856, U01HL089897, R01HL124233, R01HL147326, T32HL007427]
  2. Alpha-1 Foundation
  3. NHLBI [U01 HL089897, U01 HL089856]
  4. TOPMed Informatics Research Center [3R01HL-117626-02S1, HHSN268201800002I]
  5. TOPMed Data Coordinating Center [R01HL-120393, U01HL-120393, HHSN268201800001I]
  6. COPD Foundation
  7. Broad Genomics Institute Platform [HHSN268201500014C]
  8. Northwest Genomics Center [3R01HL089856-08S1]
  9. McDonnell Genome Institute [HHSN268201600037I]
  10. Broad Genomic Institute Platform [HHSN268201600034I]

Ask authors/readers for more resources

This study found that carriers of the AAT Z allele (MZ heterozygotes) with COPD had lower lung function and more emphysema compared to MM subjects with COPD. In addition, there were subtle differences in gene expression between the two groups, suggesting that MZ subjects may represent a subtype of COPD.
Rationale: Multiple studies have demonstrated an increased risk of chronic obstructive pulmonary disease (COPD) in heterozygous carriers of the AAT (alpha-1 antitrypsin) Z allele. However, it is not known if MZ subjects with COPD are phenotypically different from noncarriers (MM genotype) with COPD. Objectives: To assess if MZ subjects with COPD have different clinical features compared with MM subjects with COPD. Methods: Genotypes of SERPINA 1 were ascertained by using whole-genome sequencing data in three independent studies. We compared outcomes between MM subjects with COPD and MZ subjects with COPD in each study and combined the results in a meta-analysis. We performed longitudinal and survival analyses to compare outcomes in MM and MZ subjects with COPD over time. Measurements and Main Results: We included 290 MZ subjects with COPD and 6,184 MM subjects with COPD across the three studies. MZ subjects had a lower FEV1 % predicted and greater quantitative emphysema on chest computed tomography scans compared with MM subjects. In a meta-analysis, the FEV1 was 3.9% lower (95% confidence interval [CI], -6.55% to -1.26%) and emphysema (the percentage of lung attenuation areas <-950 HU) was 4.14% greater (95% CI, 1.44% to 6.84%) in MZ subjects. We found one gene, PGF (placental growth factor), to be differentially expressed in lung tissue from one study between MZ subjects and MM subjects. Conclusions: Carriers of the AAT Z allele (those who were MZ heterozygous) with COPD had lower lung function and more emphysema than MM subjects with COPD. Taken with the subtle differences in gene expression between the two groups, our findings suggest that MZ subjects represent an endotype of COPD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available